The Rising Cases of Autoimmune Diseases, Expanding Governmental Efforts to Upgrade Healthcare Systems And Increased Adoption of Cutting-Edge Technologies are Driving the Autoimmune Drugs And Disease Management Market during the Forecast Period of 2022-2027

Autoimmune Drugs And Disease Management Market Size is estimated to reach $172.3 billion by 2027 and it is poised to grow at a CAGR of 11.8% over the forecast period of 2022-2027. Autoimmune diseases are brought on by an autoimmune reaction that targets cells and destroys body tissues. Autoimmune diseases remain largely incurable. However, active disease management protocols and drugs reduce the incidence probability in the recognized patient pool. As per NCBI 2021, there are about 80 different forms of autoimmune disorders found around the globe and affecting nearly 300 million people with a higher majority of the patient pool being female. The two main drivers driving the market's expansion are the increased prevalence of autoimmune illnesses and the expanding understanding of these conditions. Additionally, the growing role of biosimilars and therapeutics focusing on single-cell therapy is projected to positively impact the market growth in the projected period.

The prevalence of various forms of recognized autoimmune disorders is growing significantly. It has driven the rise of greater disease management and awareness index in developed and developing countries. As per The Guardian 2022, it is estimated that the cases of autoimmune diseases are rising by 3-9% a year. Scientists tend to attribute environmental factors as one of the major reasons for such an increase apart from the genetic makeup of cells. As per a report from Immunology.org 2019, nearly £8.7 billion cost per year was solely attributed to rheumatoid arthritis within the U.K. while nearly £2.6 billion is spent on treating multiple sclerosis. Such expenditures are bound to increase in the projected period, increasing the demand for Autoimmune Drugs And Disease Management therapeutics.

Technological advancements such as the creation of novel biomarkers like Humira and Enbrel, compact diagnostic point-of-care devices and growing preference for laboratory robotics are expected to fuel the growth of the market throughout the forecast period. Furthermore, developing countries such as India are on a path to improving the medical service capacity by opening various hospitals and research centers, which pushes the market to leverage innovation and improve overall disease management. The Budget 2022-23 by India allocated INR 83,000 crore to the Department of Health and Family Welfare, a nearly 16.5 percent increase in comparison to the budget of INR 71,269 crore in 2021-22. Owing to such advancements, the market is expected to deliver positive returns.

In March 2021, the FDA approved a new medication for multiple sclerosis, Ponvory - a once-daily oral treatment. It has shown a decline in the annualized relapse rates and new brain lesions in people with multiple sclerosis. Moreover, in August 2022, Clene Nanomedicine registered a win for the gold-nanocrystal suspension to treat multiple sclerosis. The oral therapy CNM-Au8 is currently being tested to treat amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis.

The major players in the Autoimmune Drugs And Disease Management Market include Abbott Labs, AbbVie Inc, Amgen Inc, AstraZeneca, Roche, Johnson and Johnson, Novartis AG, Pfizer Inc, UCS S.A. and Dr. Reddy Laboratories.